Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences Inc (NASDAQ: ENSC) is a clinical-stage pharmaceutical innovator developing safer opioid therapies through its patented TAAP and MPAR technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in addressing prescription drug abuse.
Access real-time information about clinical trial milestones, regulatory submissions, and strategic partnerships. Our curated collection features press releases covering product development breakthroughs, intellectual property updates, and operational developments in pain management solutions.
Key content includes updates on abuse-deterrent formulation testing, FDA communication statuses, manufacturing collaborations, and financial performance reports. All materials maintain strict compliance with financial disclosure regulations while emphasizing patient safety advancements.
Bookmark this page for streamlined tracking of ENSC's mission to transform opioid therapy through biochemical innovation and rigorous clinical validation. Check regularly for verified updates directly from corporate communications and authorized news sources.
Ensysce Biosciences has secured $8 million in funding through a convertible note agreement with institutional investors, supporting its mission to enhance opioid safety. The financing includes senior secured convertible notes and warrants, with $4 million received in an initial closing. The funds will aid in advancing clinical studies for its abuse deterrent products. The notes are convertible at a 10% premium and bear a 6% interest rate, maturing in 18 months. The company continues to prioritize developing safer prescription drugs utilizing its unique technologies.
Ensysce Biosciences has been awarded $2.8 million for the fourth year of funding from the National Institute on Drug Abuse (NIDA) for its Multi-Pill Abuse Resistance (MPAR) platform. This funding raises total NIDA support to $10.8 million, facilitating the ongoing Phase 1 clinical trial of the PF614-MPAR opioid prodrug. CEO Lynn Kirkpatrick emphasized the grant's validation of their progress in developing safer pain relief options that deter abuse and overdose. The company is focused on delivering a market-ready MPAR drug product in the future.
Ensysce Biosciences has initiated a critical study, PF614-103, to assess the intranasal abuse potential of its drug PF614 compared to oxycodone. Conducted by Dr. Glen Apseloff, the trial aims to demonstrate that PF614 cannot be manipulated for euphoric effects by drug abusers. Chief Medical Officer Dr. Nily Osman emphasized the drug's tamper-resistant features, while CEO Dr. Lynn Kirkpatrick expressed confidence in PF614's efficacy. Results from the trial are anticipated in September 2022, marking a significant advancement in Ensysce's commitment to safer opioid alternatives.
Ensysce Biosciences reported its Q1 2022 financial results with a net loss of $1.0 million, slightly higher than the $0.9 million loss in Q1 2021. Cash reserves decreased to $8.4 million from $12.3 million at year-end 2021, driven by increased operating costs. Notably, $3.1 million was spent on R&D, up from $0.3 million in the prior year. The company announced positive results from trials PF614-102 and PF614-MPAR-101, indicating advancements in their opioid products aimed at reducing abuse and overdose risks. A corporate update call is scheduled for May 17, 2022.
Ensysce Biosciences has published its 2021 Annual Shareholder Letter, authored by CEO Dr. Lynn Kirkpatrick. The company, a clinical-stage biotech firm based in San Diego, focuses on developing safer prescription drugs using its proprietary technologies, TAAP and MPAR. These platforms aim to mitigate opioid abuse and overdose risks while offering effective pain relief. The company emphasizes its commitment to innovation in drug safety, and its extensive intellectual property portfolio supports these efforts. The letter can be viewed on their official site.
Ensysce Biosciences has announced promising results from clinical trials PF614-102 and PF614-MPAR-101. The PF614-102 study, assessing a novel oxycodone prodrug, confirmed a longer-lasting profile compared to OxyContin, indicating a potential for safer, twice-daily dosing. The PF614-MPAR-101 trial revealed early data on overdose protection capabilities of the combination product. Both studies showed favorable safety profiles, supporting Ensysce's goal of creating safer pain management options. A corporate update call is scheduled for May 17, 2022, to discuss these results further.
Ensysce Biosciences (NASDAQ:ENSC, OTC PINK:ENSCW) announced its participation in two key conferences in May 2022 focusing on opioid research. Dr. William Schmidt will present at the New York Academy of Sciences on May 3, while Dr. Lynn Kirkpatrick, CEO, will discuss critical Multi-Ascending Dose clinical data on May 5 at SMi's Pain Therapeutics Conference in London. The company aims to develop safer, tamper-proof opioids through its proprietary platforms to combat prescription drug abuse and overdose.
Ensysce Biosciences has announced the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022. She succeeds Dr. William Schmidt, who will serve as Senior VP of Clinical Development. Dr. Osman brings over ten years of experience in R&D and medical affairs in the pharmaceutical sector, enhancing the company’s leadership at a critical time. CEO Dr. Lynn Kirkpatrick highlighted Dr. Osman’s expertise in pain management as an asset for upcoming clinical trials focusing on abuse and overdose protection in opioid products.
Ensysce Biosciences reported its Q4 and full-year 2021 results, showing a net loss of $29.1 million, heavily influenced by non-cash expenses of $17.9 million related to convertible notes and warrants. Cash and equivalents increased to $12.3 million from $0.2 million year-over-year. The company successfully financed $15 million to support clinical trials, including the Phase 1 study for PF614-MPAR™, aimed at reducing opioid overdose. Federal grant funding rose to $3.5 million, despite a slight overall decrease compared to 2020. Upcoming BE data is expected to bolster regulatory efforts for PF614.
FAQ
What is the current stock price of Ensysce Biosciences (ENSC)?
What is the market cap of Ensysce Biosciences (ENSC)?
